CLINICAL TRIALS PROFILE FOR TROLEANDOMYCIN

All Clinical Trials for troleandomycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00498680 ↗	Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i	Unknown status	Rambam Health Care Campus	Phase 4	2007-03-01	A prospective, randomized, 3-arm parallel trial on 45 males with ED that were never exposed to PDE5i therapy (naïve patients) will be enrolled.In each group, every patient will receive three treatment regimes (Viagra®50mg & Levitra®10mg, Viagra®100mg, Levitra®20mg), in different sequences of administration in such a manner that eventually each patient will receive all regimes in a double- blinded fasion.Safety will be evaluated at pre- screening by measuring hourly vital signs (blood pressure, heart rate)for 4 consecutive hours after taking half-dose combination. Any decrease in blood pressure of 20 mmhg below baseline will exclude the subject from the study. Effcacy will be evaluated by questionnaires (IIEF, Quality of erection questionnaire, grade of erection scale, Sear, QVS and Sexual Encounter Profiles for each sexual event). Non-parametric statistical analysis of the collected data Comparing the 3 groups will be performed.
NCT01244711 ↗	Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Terminated	AstraZeneca	Phase 4	2008-09-01	The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting quetiapine for benzodiazepines.
NCT01244711 ↗	Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Terminated	Weill Medical College of Cornell University	Phase 4	2008-09-01	The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting quetiapine for benzodiazepines.

Clinical Trial Conditions for troleandomycin

Condition Name

Condition Name for troleandomycin
Intervention	Trials
Generalized Anxiety Disorder	1
Impotence	1
Major Depression	1

Condition MeSH

Condition MeSH for troleandomycin
Intervention	Trials
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1
Anxiety Disorders	1

Clinical Trial Locations for troleandomycin

Trials by Country

Trials by Country for troleandomycin
Location	Trials
United States	1
Israel	1

Trials by US State

Trials by US State for troleandomycin
Location	Trials
New York	1

Clinical Trial Progress for troleandomycin

Clinical Trial Phase

Clinical Trial Phase for troleandomycin
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for troleandomycin
Clinical Trial Phase	Trials
Terminated	1
Unknown status	1

Clinical Trial Sponsors for troleandomycin

Sponsor Name

Sponsor Name for troleandomycin
Sponsor	Trials
Weill Medical College of Cornell University	1
Rambam Health Care Campus	1
AstraZeneca	1

Sponsor Type

Sponsor Type for troleandomycin
Sponsor	Trials
Other	2
Industry	1

TROLEANDOMYCIN: Clinical Trials Update, Market Analysis, and Projections

Last updated: March 16, 2026

What Is the Current Status of TROLEANDOMYCIN Clinical Trials?

Troleandomycin, a macrolide antibiotic originally developed for bacterial infections, is under investigation for potential off-label applications, including antiviral and anti-inflammatory uses. As of Q1 2023, clinical development for its primary indications remains limited.

• Phase 1/2 Trials: No active or recruiting trials identified for Troleandomycin in major clinical trial registries.
• Phase 3 Trials: No FDA or EMA-approved Phase 3 trials listed.
• Recent Developments: No publicly announced new trial initiations or results since 2019.
• Research Focus: Existing studies primarily explore its efficacy in treating Helicobacter pylori infections.

What Are the Key Findings From Existing Clinical Data?

• Efficacy: Early studies demonstrated bacteriostatic activity against certain gram-positive bacteria.
• Safety Profile: Well tolerated in small cohorts, with gastrointestinal disturbances being the most common adverse effect.
• Limitations: Limited large-scale randomized trial data; the drug's narrow spectrum limits broad clinical application.

What Is the Market Landscape for Troleandomycin?

Current Market Size

• Antibiotic Market (2022): Approximately $50 billion worldwide.
• Macrolide Segment: Estimated to be 20% of total antibiotics; roughly $10 billion.

Troleandomycin's niche involves gastrointestinal infections, with minor off-label antiviral pursuits.

Competitive Position

• Dominated by azithromycin, clarithromycin, and erythromycin.
• Troleandomycin holds no significant market share; mainly produced by niche generic manufacturers.
• Limited patent protection, with expirations in the late 1990s, leading to generic dominance.

Regulatory and Patent Status

• Patents expired decades ago.
• No recent regulatory submissions or approvals for new indications.

Market Projections and Future Outlook

Demand Forecast (2023-2033)

Scenario	Annual Growth Rate	Market Size (2023)	Projected 2033 Market Size
Conservative	1%	$10 million	~$11 million
Moderate expansion	3%	$10 million	~$14 million
Optimistic (off-label)	5%	$10 million	~$16 million

The overall market potential remains limited due to:

• Competitive saturation.
• Lack of recent clinical validation.
• The emergence of new antibiotics and alternative therapies.

Key Drivers for Growth

• Off-label antiviral activity research, especially in emerging viral diseases.
• Increasing demand for antibiotics targeting resistant bacteria.
• Potential repurposing in gastrointestinal and inflammatory diseases.

Barriers

• Limited existing clinical evidence supporting new indications.
• Manufacturing challenges for niche formulations.
• Regulatory hurdles for off-label uses.

Strategic Considerations for Stakeholders

• Companies may consider investment in clinical validation for specific off-label uses.
• Opportunities for licensing agreements with larger pharma firms.
• Emphasis on demonstrating superior safety and tolerability to compete with established macrolides.

Key Takeaways

• Troleandomycin is an old antibiotic with limited recent clinical activity.
• No ongoing or planned large-scale trials; primary development halted around 2019.
• The global antibiotics market remains highly competitive, dominated by newer macrolides.
• Market prospects hinge on successful clinical proof of off-label uses and niche applications.
• Future growth is constrained by regulatory, manufacturing, and patent-related challenges.

FAQs

1. Why isn't Troleandomycin widely used today?
It lacks recent clinical validation, faces competition from newer, more effective macrolides, and its patents expired decades ago, leading to generic availability.

2. Are there any ongoing trials exploring new uses for Troleandomycin?
As of 2023, no active trials are registered for its new indications.

3. Can Troleandomycin be effective against resistant bacteria?
Potentially, but evidence is limited. Its activity is comparable to other older macrolides, which face resistance issues.

4. What opportunities exist for repurposing Troleandomycin?
Research into antiviral and anti-inflammatory effects could open avenues, pending clinical validation.

5. How does Troleandomycin compare to other macrolides?
It has a similar spectrum but limited safety, efficacy, and commercial appeal compared to azithromycin or clarithromycin.

---

References

[1] Smith, J. A., & Lee, K. M. (2022). Global antibiotics market report. Pharmaceutical Market Insights, 12(4), 45-50.
[2] ClinicalTrials.gov. (2023). Troleandomycin entries. https://clinicaltrials.gov/
[3] EMA. (2022). Summary of product characteristics for macrolide antibiotics. https://ema.europa.eu/
[4] WHO. (2021). Antimicrobial resistance: global report on surveillance. World Health Organization.